---
title: "Novo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and… — 诺和诺德 — DecisionGateway"
description: "statement by 诺和诺德, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d24c-483f-793d-9b6b-be462fc1a0f8"
meta:
  "og:description": "statement by 诺和诺德, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "Novo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and… — 诺和诺德 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **Novo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and semaglutide injection) for long-term weight management has been accepted by the National Medical Products Administration.**

A statement by [**诺和诺德**](https://dgw.tmarket.io/actors/01a1d24c-47fc-7ea7-a5d5-c0c32c8ffba8). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *诺和诺德宣布，其新药卡瑞林肽司美格鲁肽注射液（CagriSema）用于长期体重管理的上市申请获国家药监局受理。*

financial\_expressPublished 2026-11-10 [ Read source](https://t.me/financial_express/3614673)

[**诺和诺德 dossier **](https://dgw.tmarket.io/actors/01a1d24c-47fc-7ea7-a5d5-c0c32c8ffba8)

## **Related claims**

[**CagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.**界面新闻 · statement](https://dgw.tmarket.io/claims/01a1d24c-485a-7af6-9fa1-7aa87fd66188) [**CagriSema is a fixed-dose combination formulation.**界面新闻 · statement](https://dgw.tmarket.io/claims/01a1d24c-484f-7573-9a2b-d53df4512e82) [**CagriSema is injected subcutaneously once weekly.**界面新闻 · statement](https://dgw.tmarket.io/claims/01a1d24c-4866-7ab3-9a77-7683b54b7dd5) [**The FDA requires a warning about a risk of sudden blindness with popular weight-loss drugs.**noticias\_telemundo · statement](https://dgw.tmarket.io/claims/01a1c7f4-1e0b-7177-9e67-e468e56dd7bd) [**The two components act through different and complementary mechanisms of action, jointly acting on appetite and weight-regulation pathways.**界面新闻 · statement](https://dgw.tmarket.io/claims/01a1d24c-4871-7437-a1bc-e927f3d61244) [**The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad)

## **More claims by 诺和诺德**

No other claims by this actor on record.

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 3,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d24c-483f-793d-9b6b-be462fc1a0f8#webpage","@type":"WebPage","description":"statement by 诺和诺德, recorded recently — verbatim quote and source citation.","name":"Novo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and… — 诺和诺德 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d24c-483f-793d-9b6b-be462fc1a0f8","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d24c-483f-793d-9b6b-be462fc1a0f8#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d24c-483f-793d-9b6b-be462fc1a0f8"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d24c-483f-793d-9b6b-be462fc1a0f8#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"Novo Nordisk announced that the marketing application for…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d24c-483f-793d-9b6b-be462fc1a0f8#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/financial_express/3614673","text":"诺和诺德宣布，其新药卡瑞林肽司美格鲁肽注射液（CagriSema）用于长期体重管理的上市申请获国家药监局受理。","url":"/claims/01a1d24c-483f-793d-9b6b-be462fc1a0f8","spokenByCharacter":{"@type":"Person","name":"诺和诺德","@id":"/actors/01a1d24c-47fc-7ea7-a5d5-c0c32c8ffba8"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.